Abstract
Cell-mediated immunity (CMI) is critical for the prevention and control of varicella-zoster virus (VZV)-related disease. To assess CMI to VZV, a varicella skin test and interferon-γ enzyme-linked immunospot (ELISPOT) assay were both performed in healthy volunteers, and the results were compared. A total of 151 subjects were examined: 16 aged 20-29 years, 26 aged 30-39 years, 18 aged 40-49 years, 73 aged 50-59 years, and 18 aged 60-69 years. All were seropositive by a glycoprotein antigen- based enzyme-linked immunosorbent assay (gpELISA). Skin test reactivity was significantly correlated with the ELISPOT count, and both decreased with increasing age, indicating an age-dependent decline in CMI to VZV. In contrast, the antibody titer obtained by the gpELISA did not correlate with skin test reactivity. The results suggest that the skin test and ELISPOT assay are both reliable for assessing CMI to VZV and can easily be applied to screen individuals susceptible to the development of herpes zoster.
| Original language | English |
|---|---|
| Pages (from-to) | 1327-1333 |
| Number of pages | 7 |
| Journal | Journal of Infectious Diseases |
| Volume | 198 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 01-11-2008 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Infectious Diseases
Cite this
}
Measurement of Varicella-Zoster Virus (VZV)-specific cell-mediated immunity : Comparison between VZV skin test and interferon-γ enzyme-linked immunospot assay. / Sadaoka, Kay; Okamoto, Shigefumi; Gomi, Yasuyuki; Tanimoto, Takeshi; Ishikawa, Toyokazu; Yoshikawa, Tetsushi; Asano, Yoshizo; Yamanishi, Koichi; Mori, Yasuko.
In: Journal of Infectious Diseases, Vol. 198, No. 9, 01.11.2008, p. 1327-1333.Research output: Contribution to journal › Article
TY - JOUR
T1 - Measurement of Varicella-Zoster Virus (VZV)-specific cell-mediated immunity
T2 - Comparison between VZV skin test and interferon-γ enzyme-linked immunospot assay
AU - Sadaoka, Kay
AU - Okamoto, Shigefumi
AU - Gomi, Yasuyuki
AU - Tanimoto, Takeshi
AU - Ishikawa, Toyokazu
AU - Yoshikawa, Tetsushi
AU - Asano, Yoshizo
AU - Yamanishi, Koichi
AU - Mori, Yasuko
PY - 2008/11/1
Y1 - 2008/11/1
N2 - Cell-mediated immunity (CMI) is critical for the prevention and control of varicella-zoster virus (VZV)-related disease. To assess CMI to VZV, a varicella skin test and interferon-γ enzyme-linked immunospot (ELISPOT) assay were both performed in healthy volunteers, and the results were compared. A total of 151 subjects were examined: 16 aged 20-29 years, 26 aged 30-39 years, 18 aged 40-49 years, 73 aged 50-59 years, and 18 aged 60-69 years. All were seropositive by a glycoprotein antigen- based enzyme-linked immunosorbent assay (gpELISA). Skin test reactivity was significantly correlated with the ELISPOT count, and both decreased with increasing age, indicating an age-dependent decline in CMI to VZV. In contrast, the antibody titer obtained by the gpELISA did not correlate with skin test reactivity. The results suggest that the skin test and ELISPOT assay are both reliable for assessing CMI to VZV and can easily be applied to screen individuals susceptible to the development of herpes zoster.
AB - Cell-mediated immunity (CMI) is critical for the prevention and control of varicella-zoster virus (VZV)-related disease. To assess CMI to VZV, a varicella skin test and interferon-γ enzyme-linked immunospot (ELISPOT) assay were both performed in healthy volunteers, and the results were compared. A total of 151 subjects were examined: 16 aged 20-29 years, 26 aged 30-39 years, 18 aged 40-49 years, 73 aged 50-59 years, and 18 aged 60-69 years. All were seropositive by a glycoprotein antigen- based enzyme-linked immunosorbent assay (gpELISA). Skin test reactivity was significantly correlated with the ELISPOT count, and both decreased with increasing age, indicating an age-dependent decline in CMI to VZV. In contrast, the antibody titer obtained by the gpELISA did not correlate with skin test reactivity. The results suggest that the skin test and ELISPOT assay are both reliable for assessing CMI to VZV and can easily be applied to screen individuals susceptible to the development of herpes zoster.
UR - http://www.scopus.com/inward/record.url?scp=54249132503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54249132503&partnerID=8YFLogxK
U2 - 10.1086/592219
DO - 10.1086/592219
M3 - Article
C2 - 18774884
AN - SCOPUS:54249132503
VL - 198
SP - 1327
EP - 1333
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 9
ER -